Morgan & Morgan Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. KYTH
NEW YORK, June 19, 2015 /PRNewswire/ -- Morgan & Morgan announces that it is investigating potential claims against the board of directors of KYTHERA Biopharmaceuticals, Inc. ("KYTHERA" or the "Company") (NASDAQ: KYTH) concerning the proposed acquisition of the Company by Allergan.
If you purchased KYTHERA stock, and want more information about the KYTHERA takeover investigation, please contact Morgan & Morgan at 1(800) 732-5200 or email [email protected].
Under the terms of the transaction, KYTHERA shareholders would receive only $75.00 per share, payable 80% in cash and 20% in new Allergan shares. However, an analyst has set a target price of $85.00 per share.
Morgan & Morgan's investigation concerns whether the board of directors of KYTHERA breached its fiduciary duties to act in the best interests of KYTHERA shareholders.
About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to shareholder rights, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar outcome.
Contact:
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44th Street
Suite 2001
New York, NY 10036
1-800-732-5200
[email protected]
SOURCE Morgan & Morgan
Related Links
http://www.securitieslawfirm.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article